A label expansion for Mounjaro from weight loss into heart-disease prevention turns the drug from an elective, cash-pay product into something doctors treating ordinary cardiac patients can prescribe — roughly doubling the addressable market. Regulatory w

Verdict: strong Lilly, unconfirmed trade — wait for the re-rating to prove itself

The demand story here is real: per Reuters, the FDA approved Mounjaro on August 28, 2026 to reduce cardiovascular risk, and it lands on an income statement with FY2025 revenue up 44.7% to $65.2B, an 83.0% gross margin, and diluted EPS up 96%. But the trade side is not ready — the price breakout above $1,182.73 has technically fired at the $1,189.41 close, while the 14-day ADX sits at 5.3 versus the required level above 20, roughly 14.7 points away, and the on-balance volume condition cannot yet be evaluated. The bear case is closer: a close crossing below the first support at $1,163.50 negates the setup before it confirms, and the balance sheet (debt to equity of 1.54, $40.9B of long-term debt against $7.3B of cash) plus insurer-negotiated pricing in the new cardiac population leaves less room for error than the cash-pay era did. What would flip the verdict is trend strength closing above 20 with price holding above $1,182.73 and volume confirmation — that turns this from a watch-list idea into an actionable entry with a defined 2.3% stop against a 4.7% target.

Trade now

LLY closed at $1,189.41, and the price side of the entry is essentially live: the last close already sits above the nearest resistance level of $1,182.73, so the breakout half of the trigger has fired. What is missing is confirmation. The 14-day ADX is at 5.3 versus the required level above 20 — the trend-strength condition is far from triggering, by roughly 14.7 points — and the on-balance volume condition cannot currently be evaluated. This is a watch-list setup, not an active signal: the rules were evaluated on real daily bars but have not opened an entry, and the design intentionally gates the trade on a post-approval confirmation that the Mounjaro label-expansion re-rating holds, per the idea's thesis. If the entry confirms, the risk math is defined in advance. The hard stop is a 2.3% loss on the position, with a take-profit at 4.7% — an effective reward-to-risk of about 2-to-1. Price-based exits also apply: a close at or above the second resistance level of $1,200 would take profit, while a close crossing below the second support level of $1,110.57 would stop the position out. A long entry also stops if price crosses below the first support level of $1,163.50. "Wait" here means something concrete: do nothing until the trend-strength reading closes above 20 while price holds above $1,182.73 with volume confirmation intact. Chasing now would mean taking a position before the condition the setup was built around is in place. Position sizing is capped at 25% of the account with a 2.3% fixed-risk stop, so any fill keeps the dollar loss bounded. No robust parameter setup was established — the research author kept the thesis-consistent trigger as designed rather than loosening it, which is consistent with a setup whose entry is meant to be rare and catalyst-gated.

A Demand Unlock Arrives With the Numbers to Fund It

The thesis is a demand story: per Reuters, the FDA approved Mounjaro on August 28, 2026 to reduce cardiovascular risk, converting the drug from an elective, cash-pay weight-loss product into something cardiac patients can get prescribed — and, per the…

Scores

• Conviction score breakdown: 55
• Thesis support: 72
• Trade readiness: 35
• Risk quality: 55
• Trigger proximity: 30
• Fundamentals trend: 82

Watch items

• LLY — ADX (14)
• LLY — Daily close vs nearest resistance
• LLY — OBV vs price
• LLY — Daily close vs first support
• LLY — Daily close vs second support (stop level)
• LLY — Daily close vs second resistance (target)
• LLY — ADX (14) above 20